Dec 3 (Reuters) - European Medicines Agency (EMA):
- EMA: MEETING HIGHLIGHTS FROM THE PHARMACOVIGILANCE RISK ASSESSMENT COMMITTEE (PRAC) 29 NOVEMBER - 2 DECEMBER 2021: 03/12/2021
- EMA SAYS OUTCOME OF REVIEW CONFIRMS RISK OF MYOCARDITIS AND PERICARDITIS WITH COMIRNATY AND SPIKEVAX
- EMA: CONFIRMS THAT BENEFITS OF ALL AUTHORISED COVID-19 VACCINES CONTINUE TO OUTWEIGH THEIR RISKS
- EMA SAYS DETERMINED THAT RISK FOR BOTH HEART CONDITIONS IS OVERALL "VERY RARE"
- EMA SAYS DATA SHOW THAT INCREASED RISK OF MYOCARDITIS AFTER VACCINATION IS HIGHEST IN YOUNGER MALES.
Source text: (https://bit.ly/3Eo86KN)
(([email protected];))
